Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

NCT05533775 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT05533775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05533775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-Label, Single-Arm, Two-Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination With Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 16, 2022
Completion date
November 30, 2032
Enrollment
65 (estimated)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

mature b-cell non-hodgkin lymphoma